Amphastar Pharmaceuticals Q3 2026 Earnings Date & Estimates

Amphastar Pharmaceuticals (NASDAQ:AMPH) is a biopharmaceutical company that develops, manufactures and markets injectable, inhaled and intranasal products. The company focuses on technically challenging medicines, including generic and proprietary products used in emergency care, respiratory treatment, diabetes management and other therapeutic areas.

Its marketed products include Primatene MIST, an over-the-counter epinephrine inhaler for temporary relief of mild, intermittent asthma symptoms; BAQSIMI, a ready-to-use nasal glucagon product for severe hypoglycemia; glucagon injection; Amphadase, a hyaluronidase product; and enoxaparin, an anticoagulant. Amphastar also maintains a development pipeline covering additional injectable, inhaled and intranasal therapies.

Founded in 1996 and headquartered in Rancho Cucamonga, California, Amphastar serves healthcare providers, institutions and consumers primarily in the United States, with products distributed through commercial and healthcare channels. Jack Zhang, Ph.D., is the company's chairman, president and chief executive officer.